Overview
Tecentriq Hybreza is approved by the U.S. Food and Drug Administration (FDA) in combination with cobimetinib and vemurafenib for the treatment of adults with BRAF V600 mutation-positive unresectable or metastatic…
Overview
Tecentriq is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with BRAF V600 mutation-positive unresectable (inoperable) melanoma or metastatic melanoma (melanoma that has…